Kimberley Bruce
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fatty Liver | 4 | 2018 | 254 | 1.250 |
Why?
| Lipoprotein Lipase | 4 | 2022 | 69 | 1.100 |
Why?
| Non-alcoholic Fatty Liver Disease | 3 | 2019 | 284 | 1.030 |
Why?
| Prenatal Exposure Delayed Effects | 6 | 2019 | 511 | 0.990 |
Why?
| Lipoproteins | 2 | 2023 | 164 | 0.920 |
Why?
| Microglia | 2 | 2021 | 214 | 0.860 |
Why?
| Metabolic Syndrome | 3 | 2011 | 395 | 0.830 |
Why?
| Optical Imaging | 1 | 2021 | 59 | 0.790 |
Why?
| Lipid Droplets | 1 | 2021 | 21 | 0.790 |
Why?
| Glucose Intolerance | 1 | 2022 | 140 | 0.770 |
Why?
| DNA Methylation | 2 | 2023 | 511 | 0.760 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 410 | 0.740 |
Why?
| Neurodegenerative Diseases | 1 | 2021 | 98 | 0.730 |
Why?
| Circadian Clocks | 4 | 2019 | 48 | 0.700 |
Why?
| Diet, High-Fat | 8 | 2019 | 248 | 0.660 |
Why?
| Genes, Essential | 4 | 2014 | 22 | 0.600 |
Why?
| CLOCK Proteins | 1 | 2016 | 11 | 0.570 |
Why?
| Sirtuin 1 | 1 | 2016 | 30 | 0.560 |
Why?
| Maternal Nutritional Physiological Phenomena | 4 | 2014 | 157 | 0.540 |
Why?
| Disease Susceptibility | 1 | 2018 | 343 | 0.540 |
Why?
| Sirtuin 3 | 1 | 2016 | 60 | 0.530 |
Why?
| Gastrointestinal Microbiome | 1 | 2022 | 561 | 0.530 |
Why?
| Nutritional Physiological Phenomena | 2 | 2012 | 55 | 0.520 |
Why?
| Disease Models, Animal | 5 | 2019 | 3799 | 0.510 |
Why?
| Dietary Fats | 3 | 2016 | 325 | 0.500 |
Why?
| 14-3-3 Proteins | 1 | 2012 | 13 | 0.440 |
Why?
| Liver | 3 | 2016 | 1827 | 0.370 |
Why?
| Lipogenesis | 2 | 2009 | 66 | 0.370 |
Why?
| Epigenesis, Genetic | 2 | 2011 | 551 | 0.360 |
Why?
| Mitochondria, Liver | 1 | 2009 | 77 | 0.360 |
Why?
| Brain | 1 | 2021 | 2540 | 0.350 |
Why?
| Animals | 18 | 2021 | 34133 | 0.310 |
Why?
| Mice | 14 | 2021 | 15888 | 0.310 |
Why?
| Suprachiasmatic Nucleus | 2 | 2019 | 20 | 0.310 |
Why?
| Pregnancy | 9 | 2019 | 5854 | 0.300 |
Why?
| Energy Metabolism | 1 | 2012 | 783 | 0.290 |
Why?
| Gene Expression Regulation | 5 | 2021 | 2491 | 0.290 |
Why?
| Triglycerides | 3 | 2023 | 527 | 0.280 |
Why?
| Lipid Metabolism | 2 | 2021 | 482 | 0.270 |
Why?
| Mice, Inbred C57BL | 8 | 2017 | 5020 | 0.240 |
Why?
| Phenotype | 4 | 2021 | 3070 | 0.230 |
Why?
| Circadian Rhythm | 3 | 2016 | 414 | 0.220 |
Why?
| Lipodystrophy | 1 | 2022 | 18 | 0.220 |
Why?
| Hypertriglyceridemia | 1 | 2022 | 39 | 0.220 |
Why?
| Diet | 3 | 2023 | 1168 | 0.220 |
Why?
| Gene Expression Profiling | 4 | 2021 | 1625 | 0.210 |
Why?
| Tissue Adhesions | 2 | 2012 | 31 | 0.210 |
Why?
| Obesity | 4 | 2018 | 2786 | 0.200 |
Why?
| Peroxisome Proliferator-Activated Receptors | 1 | 2021 | 16 | 0.200 |
Why?
| Substrate Specificity | 1 | 2021 | 375 | 0.190 |
Why?
| Neurons | 2 | 2021 | 1345 | 0.190 |
Why?
| Inflammation | 4 | 2021 | 2598 | 0.190 |
Why?
| Ultracentrifugation | 1 | 2020 | 49 | 0.190 |
Why?
| Cholesterol, LDL | 1 | 2022 | 326 | 0.190 |
Why?
| Tobramycin | 1 | 2019 | 48 | 0.180 |
Why?
| Positron-Emission Tomography | 1 | 2021 | 308 | 0.180 |
Why?
| Exosomes | 1 | 2020 | 91 | 0.180 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2021 | 513 | 0.170 |
Why?
| Hypothalamus | 2 | 2017 | 155 | 0.170 |
Why?
| Phospholipids | 1 | 2021 | 211 | 0.170 |
Why?
| Cholesterol | 1 | 2021 | 380 | 0.170 |
Why?
| Insulin Resistance | 2 | 2022 | 1192 | 0.170 |
Why?
| Quinolines | 1 | 2019 | 127 | 0.170 |
Why?
| Photoperiod | 2 | 2016 | 55 | 0.170 |
Why?
| Precision Medicine | 1 | 2022 | 371 | 0.160 |
Why?
| Fatty Acids | 1 | 2021 | 410 | 0.160 |
Why?
| Humans | 15 | 2023 | 122796 | 0.150 |
Why?
| Cell Line | 2 | 2021 | 2785 | 0.150 |
Why?
| Pseudomonas aeruginosa | 1 | 2019 | 310 | 0.150 |
Why?
| Pravastatin | 1 | 2017 | 33 | 0.150 |
Why?
| Nuclear Receptor Subfamily 1, Group F, Member 1 | 1 | 2016 | 4 | 0.140 |
Why?
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2016 | 3 | 0.140 |
Why?
| Simvastatin | 1 | 2017 | 68 | 0.140 |
Why?
| Nanoparticles | 1 | 2020 | 329 | 0.140 |
Why?
| Fibrosis | 1 | 2019 | 497 | 0.140 |
Why?
| Sterol Regulatory Element Binding Protein 1 | 1 | 2016 | 57 | 0.140 |
Why?
| Maternal Exposure | 1 | 2018 | 148 | 0.140 |
Why?
| Glucose | 2 | 2022 | 968 | 0.140 |
Why?
| Muscular Diseases | 1 | 2017 | 108 | 0.140 |
Why?
| Hyperlipidemias | 1 | 2017 | 134 | 0.140 |
Why?
| Acidosis | 1 | 2017 | 94 | 0.140 |
Why?
| Oxidation-Reduction | 2 | 2016 | 931 | 0.130 |
Why?
| Body Composition | 2 | 2017 | 668 | 0.130 |
Why?
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2014 | 14 | 0.130 |
Why?
| Eating | 2 | 2019 | 379 | 0.130 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 196 | 0.120 |
Why?
| Proteomics | 1 | 2020 | 890 | 0.120 |
Why?
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 19 | 0.120 |
Why?
| Female | 12 | 2019 | 63629 | 0.120 |
Why?
| Biopsy | 1 | 2018 | 1090 | 0.120 |
Why?
| Weight Gain | 1 | 2017 | 511 | 0.120 |
Why?
| Adiposity | 2 | 2016 | 523 | 0.120 |
Why?
| Immunohistochemistry | 1 | 2018 | 1727 | 0.110 |
Why?
| Repressor Proteins | 1 | 2016 | 384 | 0.110 |
Why?
| Ovary | 1 | 2014 | 209 | 0.110 |
Why?
| Prenatal Nutritional Physiological Phenomena | 2 | 2009 | 66 | 0.110 |
Why?
| Appetite | 1 | 2012 | 57 | 0.110 |
Why?
| Actins | 1 | 2014 | 409 | 0.100 |
Why?
| Endometrium | 1 | 2011 | 61 | 0.100 |
Why?
| Disease Progression | 1 | 2019 | 2546 | 0.100 |
Why?
| Epithelium | 1 | 2012 | 309 | 0.100 |
Why?
| Blood Vessels | 1 | 2012 | 193 | 0.100 |
Why?
| Liver Transplantation | 1 | 2019 | 929 | 0.100 |
Why?
| Pelvic Pain | 1 | 2010 | 38 | 0.100 |
Why?
| Models, Biological | 3 | 2017 | 1756 | 0.090 |
Why?
| Magnetic Resonance Imaging | 1 | 2021 | 3264 | 0.090 |
Why?
| Electron Transport | 1 | 2009 | 101 | 0.090 |
Why?
| Hyaluronan Receptors | 1 | 2009 | 96 | 0.090 |
Why?
| Adipokines | 1 | 2009 | 46 | 0.090 |
Why?
| Polycystic Ovary Syndrome | 1 | 2011 | 158 | 0.090 |
Why?
| Intra-Abdominal Fat | 1 | 2009 | 98 | 0.090 |
Why?
| Lactation | 1 | 2009 | 162 | 0.080 |
Why?
| Genetic Variation | 1 | 2012 | 952 | 0.070 |
Why?
| Feeding Behavior | 1 | 2012 | 627 | 0.070 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2012 | 852 | 0.070 |
Why?
| Polymerase Chain Reaction | 1 | 2009 | 1021 | 0.070 |
Why?
| Body Weight | 3 | 2017 | 958 | 0.070 |
Why?
| Oxidative Stress | 2 | 2009 | 1204 | 0.070 |
Why?
| Histones | 1 | 2011 | 562 | 0.070 |
Why?
| Sleep | 1 | 2010 | 722 | 0.060 |
Why?
| Gene Expression | 3 | 2014 | 1506 | 0.060 |
Why?
| Apolipoprotein C-III | 1 | 2022 | 13 | 0.060 |
Why?
| MicroRNAs | 1 | 2009 | 661 | 0.060 |
Why?
| Signal Transduction | 1 | 2016 | 4902 | 0.050 |
Why?
| Oligonucleotides, Antisense | 1 | 2022 | 102 | 0.050 |
Why?
| Abdomen | 2 | 2012 | 117 | 0.050 |
Why?
| Chemical Precipitation | 1 | 2020 | 38 | 0.050 |
Why?
| Genetic Predisposition to Disease | 1 | 2010 | 2359 | 0.050 |
Why?
| Benzofurans | 1 | 2019 | 23 | 0.050 |
Why?
| Microbial Viability | 1 | 2019 | 82 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 346 | 0.040 |
Why?
| Microbial Sensitivity Tests | 1 | 2019 | 312 | 0.040 |
Why?
| Male | 7 | 2019 | 59639 | 0.040 |
Why?
| Chylomicron Remnants | 1 | 2017 | 1 | 0.040 |
Why?
| Calorimetry | 1 | 2017 | 59 | 0.040 |
Why?
| Risk Factors | 1 | 2011 | 9381 | 0.040 |
Why?
| Dependovirus | 1 | 2017 | 52 | 0.040 |
Why?
| Hydrolysis | 1 | 2017 | 189 | 0.040 |
Why?
| Ceramides | 1 | 2017 | 105 | 0.040 |
Why?
| Mice, Knockout | 2 | 2016 | 2737 | 0.040 |
Why?
| Calorimetry, Indirect | 1 | 2016 | 75 | 0.030 |
Why?
| Glucose Tolerance Test | 1 | 2017 | 370 | 0.030 |
Why?
| Gene Deletion | 1 | 2017 | 365 | 0.030 |
Why?
| Green Fluorescent Proteins | 1 | 2017 | 402 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2019 | 1981 | 0.030 |
Why?
| Adult | 4 | 2022 | 32385 | 0.030 |
Why?
| Algorithms | 2 | 2012 | 1593 | 0.030 |
Why?
| Time Factors | 2 | 2017 | 6682 | 0.030 |
Why?
| Homeostasis | 1 | 2017 | 596 | 0.030 |
Why?
| Organ Size | 1 | 2014 | 474 | 0.030 |
Why?
| Lipids | 1 | 2017 | 614 | 0.030 |
Why?
| Weaning | 1 | 2012 | 59 | 0.030 |
Why?
| Peritoneum | 1 | 2012 | 38 | 0.030 |
Why?
| Systole | 1 | 2012 | 178 | 0.030 |
Why?
| Gynecologic Surgical Procedures | 1 | 2012 | 49 | 0.030 |
Why?
| DNA Topoisomerases, Type I | 1 | 2011 | 15 | 0.030 |
Why?
| Animals, Newborn | 1 | 2014 | 825 | 0.030 |
Why?
| Reference Standards | 1 | 2012 | 177 | 0.030 |
Why?
| Nitric Oxide Synthase Type III | 1 | 2012 | 198 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2017 | 2079 | 0.030 |
Why?
| Femur | 1 | 2012 | 201 | 0.030 |
Why?
| Vasoconstriction | 1 | 2012 | 216 | 0.020 |
Why?
| Femoral Artery | 1 | 2012 | 182 | 0.020 |
Why?
| Peritoneal Diseases | 1 | 2010 | 4 | 0.020 |
Why?
| Menstrual Cycle | 1 | 2011 | 115 | 0.020 |
Why?
| Intestinal Obstruction | 1 | 2010 | 41 | 0.020 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2010 | 84 | 0.020 |
Why?
| Preoperative Care | 1 | 2012 | 342 | 0.020 |
Why?
| Insulin-Like Growth Factor II | 1 | 2009 | 24 | 0.020 |
Why?
| PPAR alpha | 1 | 2009 | 56 | 0.020 |
Why?
| Microarray Analysis | 1 | 2009 | 124 | 0.020 |
Why?
| Carnitine O-Palmitoyltransferase | 1 | 2009 | 48 | 0.020 |
Why?
| Analysis of Variance | 1 | 2012 | 1329 | 0.020 |
Why?
| Vasodilation | 1 | 2012 | 462 | 0.020 |
Why?
| Laparoscopy | 1 | 2012 | 426 | 0.020 |
Why?
| Nitric Oxide | 1 | 2012 | 884 | 0.020 |
Why?
| Software | 1 | 2011 | 631 | 0.020 |
Why?
| Interleukin-6 | 1 | 2010 | 702 | 0.020 |
Why?
| Up-Regulation | 1 | 2009 | 891 | 0.020 |
Why?
| Blood Pressure | 1 | 2012 | 1713 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1181 | 0.020 |
Why?
| RNA | 1 | 2011 | 854 | 0.020 |
Why?
| Chronic Disease | 1 | 2010 | 1645 | 0.020 |
Why?
| Case-Control Studies | 1 | 2011 | 3296 | 0.020 |
Why?
| RNA, Messenger | 1 | 2009 | 2720 | 0.010 |
Why?
| Biomarkers | 1 | 2009 | 3662 | 0.010 |
Why?
| Cardiovascular Diseases | 1 | 2009 | 1859 | 0.010 |
Why?
|
|
Bruce's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|